全文获取类型
收费全文 | 2778篇 |
免费 | 117篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 41篇 |
妇产科学 | 20篇 |
基础医学 | 442篇 |
口腔科学 | 22篇 |
临床医学 | 192篇 |
内科学 | 249篇 |
皮肤病学 | 761篇 |
神经病学 | 75篇 |
特种医学 | 37篇 |
外科学 | 320篇 |
综合类 | 179篇 |
预防医学 | 106篇 |
眼科学 | 6篇 |
药学 | 148篇 |
2篇 | |
中国医学 | 107篇 |
肿瘤学 | 168篇 |
出版年
2024年 | 5篇 |
2023年 | 58篇 |
2022年 | 87篇 |
2021年 | 161篇 |
2020年 | 109篇 |
2019年 | 124篇 |
2018年 | 120篇 |
2017年 | 87篇 |
2016年 | 71篇 |
2015年 | 88篇 |
2014年 | 179篇 |
2013年 | 176篇 |
2012年 | 120篇 |
2011年 | 140篇 |
2010年 | 139篇 |
2009年 | 127篇 |
2008年 | 115篇 |
2007年 | 100篇 |
2006年 | 76篇 |
2005年 | 92篇 |
2004年 | 66篇 |
2003年 | 51篇 |
2002年 | 55篇 |
2001年 | 37篇 |
2000年 | 55篇 |
1999年 | 47篇 |
1998年 | 35篇 |
1997年 | 37篇 |
1996年 | 48篇 |
1995年 | 31篇 |
1994年 | 22篇 |
1993年 | 27篇 |
1992年 | 19篇 |
1991年 | 24篇 |
1990年 | 18篇 |
1989年 | 14篇 |
1988年 | 23篇 |
1987年 | 22篇 |
1986年 | 13篇 |
1985年 | 20篇 |
1984年 | 11篇 |
1982年 | 8篇 |
1981年 | 13篇 |
1979年 | 4篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1976年 | 6篇 |
1972年 | 5篇 |
1971年 | 3篇 |
1969年 | 5篇 |
排序方式: 共有2917条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Introduction: Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas of skin-homing T-cells that initially or mainly manifest cutaneously. Treatment of CTCL is challenging given the disease states’ varying presentation and prognosis. Systemic treatment options often lack comparative evidence and have relatively low response rates and short duration of response. The recent Food and Drug Administration (FDA) approval of mogamulizumab in adult patients with relapsed or refractory (R/R) CTCL after at least one prior line of therapy provided a new treatment option to patients with advanced disease.
Areas covered: The authors discuss basic information about CTCL and mogamulizumab’s mechanism of action. Then, the authors discuss the agent’s efficacy. Finally, the authors evaluate the safety of mogamulizumab in comparison to other agents available in CTCL.
Expert opinion: Mogamulizumab has been shown to be an effective and well tolerated therapy for patients with relapsed and refractory MF/SS with excellent activity in the circulating component of the disease. 相似文献
5.
皮肤鳞状细胞癌(cSCC)是角质形成细胞来源的恶性肿瘤之一。转录组是特定条件下细胞内全部转录产物的总和,包括编码mRNA和非编码RNA。研究发现,与正常细胞相比,鳞癌细胞在基因转录水平和模式上存在很大差异,具有不同转录表达谱。微小RNA(miRNA)可通过抑制转录产物的翻译,从而调控靶基因的表达,影响cSCC细胞的增殖、分化和凋亡等病理过程。越来越多的研究表明,miRNAs作为cSCC诊断、预测预后和治疗靶点的生物标志物,在临床上具有广阔的应用前景。本文通过回顾分析cSCC的miRNA表达谱,主要对其中经实验证实表达上调和下调的miRNAs在cSCC中的研究进展作一综述。 相似文献
6.
Theodore E. Milner Claude Dugas Nathalie Picard Allan M. Smith 《Brain research》1991,548(1-2):228-241
Neural activity was recorded from the median nerve of a monkey during grasping and lifting, using a chronically implanted cuff electrode. At the onset of lifting, there was an initial dynamic response during which the intensity of the neural signal increased rapidly. This neural response attained its peak value well before the displacement, the load force or the grip force. The time course and peak of the rectified, integrated neurogram were best correlated with the rate of change of grip force. The neural activity declined exponentially to a steady value following the initial peak. During steady holding the mean amplitude of the neurogram was best correlated with the mean grip force. At the end of the holding phase there was a short burst of neural activity as the monkey relaxed the grip force and released the object. During some blocks of trials pulse perturbations were applied to the object. When the monkey did not increase the grip force in advance of the perturbation, the perturbation produced a relatively large displacement of the object and a burst of neural activity whose onset coincided with the onset of displacement. When the monkey anticipated the perturbation by increasing the grip force during the holding period preceding the perturbation, the perturbation produced a relatively small displacement and relatively little increase in neural activity. 相似文献
7.
8.
邻近皮瓣修复面部皮肤缺损 总被引:1,自引:0,他引:1
目的 探讨邻近皮瓣修复面部皮肤缺损的应用效果。方法 162例面部病变切除后皮肤缺损患者,其中先天性色素痣63例,基底细胞癌28例,鳞状细胞癌6例,其他皮肤病变65例。均采用邻近皮瓣即时修复,其中菱形皮瓣57例、双叶皮瓣8例,A-T皮瓣23例、V-Y皮瓣13例、Z成形术23例、推进皮瓣27例、鼻状皮瓣11例。结果 162例皮瓣存活良好,手术切口1期愈合,存活后皮瓣颜色与邻近部位无明显差异,术后无眼睑、眉毛、鼻梁及口角牵扯歪钭,术后3个月切口不显露。结论 邻近皮瓣是修复面部较大皮肤缺损的良好方法,手术外观效果好。 相似文献
9.
Several single agonist/antagonist primary muscle spindle afferents were simultaneously recorded in chloralose anaesthetized cats. It was shown that their dynamic and static sensitivity to sinusoidal muscle stretches could be increased or decreased via the fusimotor system by extension and flexion of the contralateral hind limb as well as by stretch of ipsilateral muscles and stimulation of ipsilateral skin nerves. The results seem to support the hypothesis that the primary muscle spindle afferents convey complex multisensory messages to the central nervous system (CNS). 相似文献
10.
Thomas A. Luger Harald Gollnick Thomas Schwennesen Raphael Bextermller Siegfried Freytag Matthias Brutigam 《Journal der Deutschen Dermatologischen Gesellschaft》2007,5(10):908-914
Background: Pimecrolimus cream 1% has proven to be well‐tolerated and effective in controlled clinical studies in patients with atopic dermatitis (AD). In a 15‐week patient self‐observation study, safety and efficacy was investigated in the daily practice. Patients and methods: 3502 patients with AD (mean age 26.2 ± 18 years, 62% female) received pimecrolimus cream 1% from 810 physicians in the German Federal Republic.The severity of the disease was assessed at baseline, two times during the 15‐week observation period and at the end of treatment.Patients recorded daily the degree of erythema and pruritus. At the end of treatment, safety and efficacy were assessed by the physician based on patient's daily records and by the patient. Results: The percentage of patients with severe or massive AD decreased from 25% to 7%, whereas the percentage of patients without or with mild symptoms increased from 9% to 55%.The efficacy of treatment was rated by physicians as good or very good in 83.5% of cases and by 79% of patients.At baseline 35% of the patients were free of flares as compared to 75% at the end of therapy. Disease control was better in patients who followed the recommended treatment algorithm for pimecrolimus cream.Tolerability was mostly rated as good or very good. Conclusion: Treatment with pimecrolimus cream 1% for patients with AD is well‐tolerated and effective in daily practice. 相似文献